



Date: November 12, 2020

RE: Cyberattack at the University of Vermont Medical Center

On October 28, 2020, a cyberattack occurred at the University of Vermont Medical Center (UVMMC). The Medical Center took quick action to protect patient information, following emergency down time procedures. On the morning of 10/29/2020, UVMMC made the decision to disconnect all internet connections and external network connections. The medical center is working with state and federal law enforcement to determine the full scope of this attack. The UVM Larner College of Medicine (LCOM) and University of Vermont have blocked access to UVMMC until the situation is resolved. Presently UVMMC Email is not operational externally as a precaution but LCOM Email is fully functional. External emails sent to the UVMMC servers may be returned as a result. Computers used by the Clinical Trials Office (CTO) staff are not on the infected network. Our CTO staff reside in the LCOM and our records are secure. The LCOM server has not been affected by the cyberattack. CTO staff do have access to the internet.

Electronic medical record (EMR) access at UVMMC is limited but VITL (Vermont Health Information Exchange) access has been granted to our clinical research supervisor and paper source documents are available for documentation. The CTO maintains a separate patient calendar with patient visits and information regarding protocol related needs on a separate server at the LCOM where the CTO offices are physically located. Information related to research patients is being documented on CTO internal paper source documents (printed); dictation is also available for investigators.

Some research patients have had protocol-related testing rescheduled to still fall within the window of the allowable protocol requirements. We are making every effort to schedule any delayed activities as soon as possible to prevent/minimize protocol deviations. Patient safety and adverse event reporting documentation is provided to CTO as it becomes available. We will be communicating with sponsors regarding patient specific updates. Some monitoring visits may also need to be delayed/rescheduled. Investigational drug is secure with manual temperature tracking in place. Storage and monitoring of patient samples on site, as well as kit inventory, reagent storage, and other CTO lab processes and functions have not been impacted by the cyberattack

Please feel free to contact me should you have any additional questions.

Diana D. Naser PhD, APRN
Director, Clinical Trials Office, University of Vermont Cancer Center
Email: diana.naser@med.uvm.edu
Mobile Phone: (913) 526-2937